A concise review on Development and Assessment of Ondansetron Hydrochloride-Loaded Transdermal Patches

Ondansetron hydrochloride (HCl), a 5-HT3 receptor antagonist, is widely utilized to prevent nausea and vomiting, particularly in chemotherapy patients. Despite its therapeutic efficacy, its brief biological half-life and first-pass metabolism limit its bioavailability through conventional routes. Transdermal drug delivery offers a controlled and sustained release profile, thereby improving adherence to therapy. This review explores diverse strategies for the development and analysis of Ondansetron HCl transdermal patches, with a focus on polymer selection, film-forming techniques, and physicochemical property evaluation.